Get the Stockscreener App
66.82
0.46%
-0.31
After Hours:
66.82
Disc Medicine Inc stock is traded at $66.82, with a volume of 342.50K.
It is down -0.46% in the last 24 hours and down -4.15% over the past month.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
See More
Previous Close:
$67.13
Open:
$67.18
24h Volume:
342.50K
Relative Volume:
0.65
Market Cap:
$2.55B
Revenue:
-
Net Income/Loss:
$-212.18M
P/E Ratio:
-11.16
EPS:
-5.9897
Net Cash Flow:
$-181.33M
1W Performance:
-0.06%
1M Performance:
-4.15%
6M Performance:
-27.84%
1Y Performance:
+39.09%
1-Day Range:
$66.65
$69.31
1-Week Range:
$63.79
$69.72
52-Week Range:
$40.00
$99.50
Disc Medicine Inc Stock (IRON) Company Profile
Name
Disc Medicine Inc
Sector
Industry
Phone
(617) 674-9274
Address
321 ARSENAL STREET, SUITE 101, WATERTOWN
Compare IRON vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IRON
Disc Medicine Inc
|
66.82 | 2.56B | 0 | -212.18M | -181.33M | -5.9897 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Disc Medicine Inc Stock (IRON) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-03-25 | Resumed | Stifel | Buy |
| Jul-21-25 | Initiated | Truist | Buy |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| Jun-11-25 | Resumed | Raymond James | Strong Buy |
| Feb-27-25 | Initiated | TD Cowen | Buy |
| Nov-05-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-04-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Oct-23-24 | Initiated | Jefferies | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Aug-22-24 | Initiated | Wells Fargo | Overweight |
| Apr-01-24 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-19-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-09-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Jun-07-23 | Initiated | H.C. Wainwright | Buy |
| May-17-23 | Initiated | Raymond James | Outperform |
| Apr-28-23 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-21-23 | Initiated | Stifel | Buy |
| Apr-20-23 | Initiated | Morgan Stanley | Overweight |
| Mar-23-23 | Initiated | BMO Capital Markets | Outperform |
| Feb-28-23 | Initiated | SVB Securities | Outperform |
View All
Disc Medicine Inc Stock (IRON) Latest News
Disc Medicine Eyes Mid-2026 Bitopertin Approval as EPP Trial Demand Surges - Yahoo Finance
Class action lawsuit launched over Disc Medicine's FDA drug rejection causing 22% stock drop - Pluang
IRON Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are ... - Caledonian Record
IRON Investor News: If You Have Suffered Losses in Disc - GlobeNewswire
Why (IRON) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Eagle Health Investments LP Purchases Shares of 27,100 Disc Medicine, Inc. $IRON - MarketBeat
Disc Medicine faces class action after FDA rejects drug application, stock drops 22%. - Pluang
IRON: APOLLO study enrollment exceeded targets, signaling high demand and unmet need for EPP therapies - TradingView
DNB Asset Management AS Raises Stock Holdings in Disc Medicine, Inc. $IRON - MarketBeat
First Light Asset Management, LLC's Disc Medicine Inc(IRON) Holding History - GuruFocus
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inqui - GuruFocus
Disc Medicine faces class action after FDA rejects drug application, stock drops 22% - Pluang
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action InvestigationIRON - The Norfolk Daily News
UBS Group AG Reduces Holdings in Disc Medicine, Inc. $IRON - MarketBeat
Should Disc Medicine’s RALLY-MF Data and Wider Pipeline Reveal a Pivotal Inflection for IRON’s Narrative? - simplywall.st
Disc Medicine, Inc.Common Stock (NQ: IRON - FinancialContent
IRON Maintained by Morgan Stanley -- Price Target Raised to $80. - GuruFocus
Cantor Fitzgerald Remains a Buy on Disc Medicine (IRON) - The Globe and Mail
Morgan Stanley Raises Price Target on Disc Medicine to $80 From $75, Keeps Overweight Rating - marketscreener.com
Understanding Momentum Shifts in (IRON) - Stock Traders Daily
IRON Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights - GlobeNewswire Inc.
Disc Medicine, Inc. Announces Oral Presentation of Phase 2 RALLY-MF Trial Data for DISC-0974 at EHA 2026 Congress and Corporate Update Call - Quiver Quantitative
Experimental anemia treatment shows 70% response in myelofibrosis trial - Stock Titan
Vanguard Group Inc. Acquires 319,621 Shares of Disc Medicine, Inc. $IRON - MarketBeat
H.C. Wainwright Sticks to Its Buy Rating for Disc Medicine (IRON) - The Globe and Mail
Stifel Maintains Disc Medicine(IRON.US) With Buy Rating, Maintains Target Price $111 - Moomoo
Hear Disc Medicine leaders in two live investor conference webcasts - Stock Titan
Disc Medicine to Participate in Upcoming Investor Conferences - FinancialContent
Number of shareholders of Disc Medicine, Inc. – NASDAQ:IRON - TradingView
Press releases provided by CNW - Techaeris
A Look At Disc Medicine (IRON) Valuation As Key APOLLO Phase 3 And Pipeline Milestones Progress - Sahm
Disc Medicine, Inc. (IRON) Eps Diluted (TTM) - Zacks Investment Research
HC Wainwright Cuts Earnings Estimates for Disc Medicine - MarketBeat
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc.IRON - PR Newswire
Disc Medicine FY2030 EPS Forecast Raised by HC Wainwright - MarketBeat
H.C. Wainwright Maintains Disc Medicine(IRON.US) With Buy Rating, Maintains Target Price $118 - Moomoo
Disc Medicine (IRON) Receives a Buy from H.C. Wainwright - The Globe and Mail
BMO Capital Maintains Disc Medicine(IRON.US) With Buy Rating, Maintains Target Price $100 - Moomoo
Truist Financial Maintains Disc Medicine(IRON.US) With Buy Rating, Maintains Target Price $83 - Moomoo
A Look At Disc Medicine (IRON) Valuation After Legal Probes And FDA Complete Response Letter - Yahoo Finance
Disc Medicine Q1 Net Loss Widens - Moomoo
Disc Medicine (NASDAQ:IRON) Releases Quarterly Earnings Results, Misses Estimates By $0.03 EPS - MarketBeat
Earnings Flash (IRON) Disc Medicine Posts Q1 Net Loss $1.65 a Share, vs. FactSet Est of $1.65 Loss - marketscreener.com
Disc Medicine (NASDAQ: IRON) posts wider Q1 loss but holds $730M cash - Stock Titan
Disc Medicine 1Q 2026: Net income $(63.5M), EPS $(1.65) — 10-Q Summary - TradingView
Earnings Flash (IRON) Disc Medicine Posts Q1 Net Loss $1.65 a Share, Vs. FactSet Est of $1.65 Loss - Moomoo
IRON: Phase 3 bitopertin trial enrollment completed; strong cash position supports pipeline into 2029 - TradingView
Disc Medicine finishes Phase 3 rare-disease trial, eyes Q4 data - Stock Titan
IRON: Net loss widened to $63.5M in Q1 2026 as bitopertin's FDA review was delayed for more data - TradingView
Disc Medicine (NASDAQ: IRON) posts Q1 2026 loss and advances late-stage trials - Stock Titan
Disc Medicine | 8-K: Disc Medicine Reports First Quarter 2026 Financial Results and Provides Business Update - Moomoo
Disc Medicine Inc Stock (IRON) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.98%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):